CTLA4 and pancreatic neoplasm: These responses were consistent against the various solid tumors including MDA-MB231 breast cancer cells (33% CTLA-4− proliferation, 30% PD1− proliferation), SW480 colon cancer cells (14% CTLA-4− proliferation, 13% PD1− proliferation) or Panc1 pancreatic cancer cells (16% CTLA-4− proliferation, 12% PD1− proliferation).